NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • About Patient and Public Involvement
      • Our Work with Patients and the Public
      • Learn More About Our Research
      • Patient Involvement Blog
      • External Links
    • For Patients, Carers and the Public
      • Current Listings for Involvement
      • REGISTER INTEREST
      • Patient and Public Involvement Workshops
    • PPI Resources for Researchers
      • PPI Strategy
      • A Researcher’s Guide to PPI
      • PPI Resources for Researchers
      • PPI Briefing Notes
      • PPI Case Studies
      • PPI Advisory Group
      • PPI Events for Researchers
      • Post a PPI Listing
      • Public Engagement for Researchers
      • Public Engagement Case Studies
  • Training Hub
    • Training Hub
    • Fellowships
    • Funding Opportunities
    • Clinical Researchers and Scientists
    • Nurses, Midwives and Allied Health Professionals
    • Next Generation Leaders Programme
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events
Research Theme

Haematology and Stem Cells

You are here: Home > Research Themes > Haematology and Stem Cells > Sub-Theme: Red Cells

Sub-Theme: Red Cells

Some people are born with anaemia inherited from their parents, while others develop anaemia later in their lives through other causes. Together these two forms of anaemia affect nearly a quarter of the world’s population, with profound effects on people’s health and the economy. Our centre brings together world leaders in anaemia research with the excellent clinical service provided in Oxford. Our research studies are looking at:

• Rare anaemia
• The role of iron metabolism in anaemia
• Anaemia and Myelodysplastic Syndrome (MDS)

Rare Anaemias

Our group is particularly interested in the genetics of red cell disorders. We use a range of genetic technologies to investigate the cause of the more commonly inherited anaemia, thalassaemia, and the rare inherited anaemias such as Congenital Dyserythropoietic Anaemia (CDA). In the long term, we hope that by combining state-of-the-art laboratory techniques with the Oxford clinical service, we will improve both diagnosis and treatments.

Our group also includes the national lead on studies of non-cancerous blood diseases, the NIHR Rare Diseases – Translational Research Collaboration website. (RD-TRC). The RD-TRC funds projects which investigate the physical characteristics and symptoms of rare genetic disorders. Current projects include work on inherited anaemias, Factor XI deficiency, inherited platelet disorders and paediatric (MDS) myelodysplastic syndromes.

(photo by Kevin Clark)

Piecing the puzzle together: Congenital Dyserythropoietic Anaemia Type 1 (CDA-1)

CDA-1 is a very rare (one in a million) type of inherited anaemia. Patients range from requiring monthly blood transfusions to survive, to being tired and prone to absorbing excess iron from their diet. There is only one specific treatment for this condition, but not everyone responds to it and the side effects can be crippling. Only by understanding what goes wrong inside the cells can we come up with new treatments. In this photo is a red blood cell precursor from a patient with CDA-1- all of the little white holes should not be there. We have found some of the pieces of the puzzle to explain why that may be the case, but are missing some critical ones to complete the picture.

The Role of Iron Metabolism in Anaemia

Anaemia can also be caused by abnormalities in iron metabolism in the body. Our researchers are studying the molecular control of normal and abnormal iron metabolism, by focusing on the molecule hepcidin. In the last decade, hepcidin has emerged as the master regulatory hormone of iron metabolism. High levels of hepcidin inhibit iron absorption from the gut and inhibit the release of iron from storage cells, both of which decrease the amount of iron available for red blood cell production. This can contribute to anaemia and lead to a poor response to iron tablets. Our researchers are exploring whether measuring hepcidin levels in patients is a useful way to predict which patients will respond well to iron tablets. We would also like to find ways to decrease hepcidin levels, so that more iron is supplied to red blood cells, enabling a better recovery from anaemia.

Anaemia and Myelodysplastic Syndrome (MDS)

Professor Boultwood’s team investigates the molecular basis of MDS, a disorder affecting bone marrow cells. In patients with MDS, the production of all blood cell types is reduced, including red cells which leads to anaemia.

The team has previously shown that abnormalities in ribosomes (important protein factories in all cells) underlie the anaemia in the 5q-syndrome, a subtype of MDS. Prof. Boultwood and her team are currently studying what happens when drugs called translation enhancers (eg. L-leucine) and other drugs which have been shown to improve the anaemia in MDS (eg. ACE-536) with the aim to identify suitable MDS therapeutics.

Haematology and Stem Cells Theme

  • Introduction
  • Our Sub-Themes
    • Blood Cancer and its Treatment
    • Red Cells
    • Transfusion and Controlling Blood Loss and Abnormal Clotting
  • Patient and Public Involvement (PPI) with the Haematology and Stem Cells theme
  • Oxford Blood Group
    • Exchange Newsletters and related news
  • Contacts
  • Videos for this theme
  • News for this theme
Oxford Blood Group for Patients

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced bimonthly and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2021 NIHR Oxford Biomedical Research Centre

Cookies

This site uses cookies See our data control and privacy page